OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO(TM) Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting

Stock Information for OncoSec Medical Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OncoSec Medical Incorporated

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO(TM)-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.